News

With the distribution agreement, Ocugen will have the rights to the vaccine candidate in the US and will also be accountable for clinical development, regulatory approval and commercialisation

The Couvet site is a state-of-the-art manufacturing facility with commercial-scale capacity to produce capsule and tablet dosage forms. For WuXi STA, the Couvet site will be its first

The antibody therapies, which are administered via intravenous infusion, have secured Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for treating high-risk patients mild

The authorisation was granted after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency reviewed the primary data from the vaccine’s Phase III

The study was led by Torri Metz of University of Utah Health and Rebecca Clifton of George Washington University’s Milken Institute School of Public Health. When compared to

The study aims to identify the types of lung cells targeted by the virus and the resulting reaction due to the infection. In some of the most severe

As per the agreement, Sanofi will manufacture 125 million doses of the Covid-19 vaccine in Europe. Initial supplies of vaccine are expected to come out of Sanofi’s facilities

As per the study which was published in the journal Cancer Research, the clinical trial showed positive results of the drug palbociclib in a specific type of triple

BIO 300 is Humanetics’ drug candidate which is expected to counteract and relieve not only severe and chronic inflammatory diseases but also radiation toxicities. The progressive pulmonary inflammation